Healthcare Companies in Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.

In response to the increasing challenge facing the healthcare sector, a group of renowned scientists, medical doctors, entrepreneurs and academic figures is launching a unique endeavour: healthbank. At healthbank we are building the world’s first people-owned health data transaction platform. healthbank will connect data sources from all facets of the healthcare ecosystem and reward participants for sharing their data for research purposes. Based in Switzerland, healthbank will leverage the advantages of Swiss neutrality, trust, and data privacy to enable users, researchers, and organisations with large data sets, to unlock the value of health and medical data on our independent, global transaction platform. healthbank is organised as a Swiss Cooperative that is fully owned and governed by its members. Its purpose is to empower users to store, access, manage and share and gain returns from their personal health information according to their needs. Our vision is to play an active role in raising people’s awareness of health beyond illness, by providing self-governed, user-centric participative platforms and value-added services that enable health data accessibility, protection and rewards.

Heart Force is about to break new ground in the early detection of heart disease. Through the assessment of the cardiac performance with a new unique technology we are able to detect coronary artery diseases at an early stage. Our Cardiac Performance Metrics represent a new capability for analyzing cardiac timing, rhythm and strength not found in the personal monitoring and screening space. Cardiovascular disease (CVD) is the number one cause of death globally (Source: WHO). Early detection is the missing key to successfully combat CVD, but difficult to achieve; CVD often does not show any symptoms. Through Heart Force it will be possible to self monitor the overall heart health and spend a life with more clarity concerning the overall heart health.

Our mission is to create a comprehensive, patient-centric ecosystem that empowers individuals and healthcare professionals alike through a unique digital health platform to bring more quality of life for everyone.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Aktiia – Bringing blood pressure monitoring to daily life Aktiia was founded in 2018 to commercialize its proprietary cuffless optical Blood Pressure Monitoring technology (oBPM™) in order to contribute to the prevention of high blood pressure, to save lives and to help reduce healthcare costs worldwide. aktiia is headquartered in Neuchatel (Switzerland) with offices opening up in Zurich (Switzerland) and the USA.

ALEVA is 👉THE COMPANY THAT INTRODUCED Directional Deep Brain Stimulation in Neuromodulation treatments and our clinically proven technology has set the industry standard for directional leads* Today we are 👉A SOLID COMPANY that following directSTIM™'s CE marking have started our commercial journey by partnering with the most important neurological clinics in Germany, with the goal to soon reach the most relevant European markets. We understand that if we want to help OUR CUSTOMERS, overcome their challenges, we need to 👉COMBINE SPECIALISATION with the 👉COMMITMENT TO BE RESPONSIVE to the everyday new challenges they experience. This is the attitude you will find in every ALEVA employee and sales representative who will be in contact with you. We are the 👉ONLY EUROPEAN COMPANY that designs, manufactures, and commercialises DBS devices for the treatment of Parkinson’s disease and essential tremor. Our production and R&D headquarters based in Switzerland complies to the highest quality standard for the highest safety of patients worldwide. Our A VISIONARY PROJECT SUSTAINED BY SOLID FOUNDATIONS: 👉a new group of investors that will sustain the completion of OUR PROJECT 👉a reinforced executive team who is complementing the existing successful group to partner with Neurosurgeons and Neurologists in the effective deployment of our Vision. *May 28, 2014 http://doi.org/10.1093/brain/awu102.

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalised medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. With our innovative technology we are creating a patient centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonise, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries in five continents, providing standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, please visit www.bcplatforms.com.

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.

Our mission is to radically improve early detection of brain disorders. We combine Virtual Reality and Artificial Intelligence to empower ophthalmologists and neurologists with reliable measurements of eye and pupil movements. Our goal is to bring the diagnostic quality of highly trained tertiary care specialists where it is needed most, in primary and secondary care. 🏆 Ypsomed Innovation Award 2022 🏆 IMD Startup Competition 2022/23 🚀 Massachusettes Innovation Network, Global Eddies 2023

MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.

ABCDx is revolutionising stroke management with the first mobile brain diagnostic platform that turns smartphones into medical devices. We equip healthcare providers with accessible tools to accurately diagnose stroke patients at point-of-care – and within only a few minutes. By pioneering the ability to decode chemical messages of the brain (brain biomarkers), we developed a clinically validated method to detect brain injury using just a single drop of blood from a finger prick. Interested to learn more or be part of the first mobile brain diagnostic platform? Our team would love to hear from you: https://www.abcdx.es/contact

EarlySight aims to reduce vision loss by enabling efficient detection and better monitoring of eye diseases. The company develops a high-performance eye imaging instrument empowering doctors to see the first disease impacts. Our technology allows to visualize the morphology of many cells in the retina that are playing key roles in the disease degenerative process and that were invisible to ophthalmic instruments before. According to ophthalmologists, it will greatly improve the detection and monitoring of many diseases such as age-related macular degeneration. It will also provide quantitative evidence of treatment efficacy and speed up the development of new therapies. With EarlySight technology, assessing the retina state of health and monitoring treatment effects can be done non-invasively in only few seconds, without having to wait months for visual acuity changes.

Timeline (parent company Amazentis) is an innovative, dynamic and growing biotech company positioned in the nutrition and skin health sectors and is located in the multicultural region of Lausanne, Switzerland. Acting at the intersection of the food and pharma industries, Amazentis employs best-in-class science to discover and develop new products to increase longevity, manage specific health needs, and support an active lifestyle.

Biolux Medical is biotechnology company that specializes in photomodulation.

Genkyotex has become a wholly owned subsidiary of Calliditas and have been delisted from the Euronext stock exchanges. Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in 318 patients with primary biliary cholangitis (PBC). As previously announced in August 2021, Calliditas received FDA fast track designation for setanaxib in PBC. Calliditas will also initiate a Phase 2 proof-of-concept study in head and neck cancer in 2021, which will investigate the administration of setanaxib in conjunction with immunotherapy targeting cancer associated fibroblasts (CAFs). Follow @Calliditas Therapeutics for updates on future developments: https://www.linkedin.com/company/calliditas-therapeutics/

GliaPharm is a Swiss-based biotechnology company that develops treatments for neurological and psychiatric disorders. GliaPharm's innovative therapeutic approach is to target glial cells, the 'support cells' of neurons, to sustain and enhance brain metabolism in pathological conditions. Our vision is to become a leading biotechnology company with a focus on glia-mediated pathways as agents for neuroprotection and maintenance of cognitive functions.

Loop medical is developing a painless blood collection technology compatible with existing laboratory infrastructure.

Lumendo, founded in 2018 and ISO 13485 certified, aims to disrupt the endodontic device market in the US and EU. Our mission is to develop the most advanced solution for this very challenging dental procedure with a disruptive cleaning technology and a novel, light-activated filler, thus helping people to keep their natural teeth longer.

Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey. At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancer drug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development. Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners. This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient.

At Neurosoft Bioelectronics, we strive at improving the care of patients who suffer from neurological disorders by developing soft implantable electrodes to interface with the nervous system. We have established a unique technology that allows to manufacture extremely compliant neural interfaces that can achieve long-term bio-integration in the body. These devices will improve therapeutic outcomes in patients as well as open up new applications for neural interfaces that were so far impossible.

Vertiefe Deine Yoga-Praxis und Dein Wissen mit der Kundalini Yoga Ausbildung. Angeboten als 4 In-Person Trainings in Zürich und einem 4 tägigen Retreat im Berneroberland. Der live Unterricht wird ergänzt durch Online Klassen die Dir ermöglichen Deinen Stundenplan individuell zu gestalten.

Leading the world to embrace movement's full potential.